Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Automation
IT & Software
Return to: PBR Home | Automation | IT & Software | News
Search Refinements

IT & Software News

View news from other Pharmaceutical sectors:
91-105 of 1702 results
Pulmatrix issued patents covering iSPERSE technology to treat patients with inhaled dry powders
Pulmatrix (PULM) has been granted two patents from the US Patent and Trademark Office (U.S. Patent # 8,992,983 and US patent # 9,061,352), which cover the composition of matter for the company's underlying iSPERSE (inhaled Small Particles Easily Respirable and Emitted) inhaled dry powder technology as well as methods for treating a subject using respirable dry powders.
Automation > IT & Software > News
Acorda awarded grant to study ARCUS Technology in respiratory distress syndrome
Acorda Therapeutics announced that the Bill & Melinda Gates Foundation has awarded the Company a $1.4m grant to support the development of a formulation and delivery system for a dry powder version of lung surfactant, a drug used to treat neonatal respiratory distress syndrome (RDS).
Automation > IT & Software > News
Medimmune, Sheffield University to research in cell factory technology
By PBR Staff Writer
AstraZeneca's global biologics R&D arm MedImmune has entered into a five-year multi-project research collaboration with the University of Sheffield to carry out breakthrough research in cell factory technology process.
Automation > IT & Software > News
Eisai, JCR to discover new CNS treatments using BBB penetration technology
By PBR Staff Writer
Eisai and JCR Pharmaceuticals have concluded a feasibility study agreement, which will examine the possibility of applying JCR's blood-brain-barrier (BBB) penetration technology 'J-Brain Cargo' to discover new treatments.
Automation > IT & Software > News
ContraFect gets key patent from USPTO covering new Lysin technology
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,034,322.
Automation > IT & Software > News
Cellecta receives NIH SBIR grant to develop validated CRISPR knockout library of guide RNA (sgRNA) sequences
Cellecta, a US-based functional genomics company, announces the receipt of Phase I SBIR grant funds from the National Institute of Health (NIH) to further its CRISPR-mediated genome-editing program.
Automation > IT & Software > News
NantHealth acquires Harris Healthcare Solutions
NantHealth, a subsidiary of NantWorks, announced it has completed the acquisition of Harris Corporation’s commercial Healthcare Solutions business, a clinical systems integration innovator. Harris retained its government healthcare services business.
Automation > IT & Software > News
Amgen reports Phase II trial results of Blincyto in patients with Ph+ B-cell precursor ALL
By PBR Staff Writer
Amgen has reported positive top-line results from an investigational Phase II trial, which was designed to evaluate the efficacy and safety of Blincyto (blinatumomab) in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL).
Automation > IT & Software > News
Panther closes acquisition of technology assets of Faulk Pharmaceuticals
Panther Biotechnology, a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, is pleased to announce that it has closed definitive agreements with privately held Faulk Pharmaceuticals to acquire Faulk's pharmaceuticals technology assets.
Automation > IT & Software > News
Argos completes patient enrollment in Phase III ADAPT trial of AGS-003
Argos Therapeutics, an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, announced the pivotal phase 3 ADAPT clinical trial of AGS-003 in combination with standard targeted therapy for the treatment of metastatic renal cell carcinoma (mRCC) has reached its enrollment goal of at least 450 randomized patients.
Automation > IT & Software > News
Medgenics begins enrollment in Phase II trial of TARGT-EPO to treat anemia in ESRD patients
By PBR Staff Writer
Medgenics has started patient enrollment in its US-based Phase II clinical trial of MDGN-201 (TARGTEPO), an investigational gene therapy to treat anemia in end stage renal disease (ESRD) patients undergoing peritoneal dialysis.
Automation > IT & Software > News
OmniComm Systems signs reseller agreement with Tri-I Biotech Shanghai
OmniComm Systems, a global leading provider of clinical data management technology and services, today announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai, a market leading China based consultancy providing high performance informatics solutions to over 1,000 medical and clinical research organizations across China, Hong Kong, Macau and Taiwan.
Automation > IT & Software > News
WuXi PharmaTech's subsidiary STA enters into private placement agreement
WuXi PharmaTech (Cayman), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the US, announced that SynTheAll Pharmaceutical, WuXi's small-molecule manufacturing subsidiary, has entered into an agreement in connection with a planned private placement of 7,160,000 common shares of STA stock, representing approximately 6% of STA's current shares outstanding, for RMB 498,694,000 in cash, or approximately $80m at current exchange rates.
Automation > IT & Software > News
Seattle Genetics begins Phase II trial of Adcetris to treat lupus
By PBR Staff Writer
US-based biotechnology firm Seattle Genetics has started a Phase II clinical trial of its antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) to treat patients with systemic lupus erythematosus (SLE or lupus), a chronic autoimmune disease.
Automation > IT & Software > News
Apceth, Cologne University to develop combination cellular immunotherapies for cancer
By PBR Staff Writer
Germany-based biopharmaceutical firm apceth has entered into collaboration with University of Cologne's Center for Molecular Medicine Cologne (CMMC) to combine technologies and expertise of both the entities to develop new immunotherapies for solid tumors and haematological malignancies.
Automation > IT & Software > News
91-105 of 1702 results